Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. (2023)
Attributed to:
Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.104188
Publication URI: https://www.repository.cam.ac.uk/handle/1810/361197
Type: Journal Article/Review